Amgen Inc. Impairment of Long-Lived Assets Held-for-use
Amgen Inc. (AMGN) reported Impairment of Long-Lived Assets Held-for-use of $97.00 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2015-02-19
- Amgen Inc. impairment of long-lived assets held-for-use for the quarter ending 2010-12-31 was $118.00M.
- Amgen Inc. impairment of long-lived assets held-for-use for fiscal 2014 was $97.00M, a 410.53% increase from fiscal 2013.
- Amgen Inc. impairment of long-lived assets held-for-use for fiscal 2013 was $19.00M, a 89.33% decline from fiscal 2012.
- Amgen Inc. impairment of long-lived assets held-for-use for fiscal 2012 was $178.00M, a 2866.67% increase from fiscal 2011.
- Amgen Inc. impairment of long-lived assets held-for-use for fiscal 2011 was $6.00M, a 94.92% decline from fiscal 2010.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|
| 2014-12-31 | $97.00M 10-K · filed 2015-02-19 | |
| 2013-12-31 | $19.00M 10-K · filed 2015-02-19 | |
| 2012-12-31 | $178.00M 10-K · filed 2015-02-19 | |
| 2011-12-31 | $6.00M 10-K · filed 2014-02-24 | |
| 2010-12-31 | $118.00M 10-K · filed 2012-02-29 | $118.00M 10-K · filed 2013-02-27 |
| 2009-12-31 | $21.00M 10-K · filed 2012-02-29 | |
| 2008-12-31 | $59.00M 10-K · filed 2011-02-25 | |
| 2007-12-31 | $404.00M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |